Bcr-Abl is found in more than 95% of cases with CML. The mechanism of Bcr-Abl-induced transformation is not fully understood. Bcr-Abl is a constitutively active tyrosine kinase with transforming ...

The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...

IL-3 protects p210 Bcr-Abl-transformed 32D and Baf3 cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors During our preliminary studies with PD180970, we found that the viability of ...

Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...

As the disease progresses, it’s important to regularly adapt treatment strategies based on consistent monitoring of BCR-ABL levels. This allows doctors to track the disease’s progression and ...

The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 ...

Terns Pharmaceuticals ( ($TERN) ) has issued an announcement. On February 22, 2025, Terns Pharmaceuticals announced the appointment of Andrew ...

The Radich laboratory was one of the first to document that monitoring levels of the abnormal, CML-promoting “BCR-ABL” fusion protein can be used to detect “minimal residual disease” and predict ...

Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR ...